Results 141 to 150 of about 862 (170)

Cleavage of cellular substrate porcine gasdermin D by porcine torovirus 3C-like protease induces pyroptosis. [PDF]

Virulence
Pan D, Liu XE, Hong X, Liu Y, Yin PF, Zeng JW, Lv Q, Du EZ, Fan W, Yang YL, Shi F, Wang B, Dong B, Huang YW.   +13 more
europepmc   +1 more source

Virus-like particle-based liquid phase blocking ELISA for evaluating the efficacy of O-type foot-and-mouth disease vaccines. [PDF]

Appl Microbiol Biotechnol
Zhang Y, Wei T, Ren M, Mu S, Bai M, Yin S, Sun S, Guo H, Dong H.   +8 more
europepmc   +1 more source

Enfermidades em suínos emergentes e reemergentes: no Brasil. [PDF]

, 2016
MORES, N., ZANELLA, J. R. C.
core  

Rapid detection of high consequence and emerging viral pathogens in pigs. [PDF]

Front Vet Sci
Neujahr AC, Loy DS, Loy JD, Brodersen BW, Fernando SC.   +4 more
europepmc   +1 more source

First report and genetic characterization of Seneca Valley virus (SVV) in Chile

Transboundary and Emerging Diseases, 2022
Seneca Valley virus (SVV) is a non-enveloped RNA virus and the only member of the Senecavirus A (SVA) species, in the Senecavirus genus, Picornaviridae family. SVV infection causes vesicular lesions in the oral cavity, snout and hooves of pigs. This infection is clinically indistinguishable from trade-restrictions-related diseases such as foot-and ...
Benjamín Bennett, Constanza Urzúa‐Encina, Catalina Pardo‐Roa, Naomi Ariyama, Claudio Lecocq, Carlos Rivera, Catalina Badía, Paulina Suárez, Michel Agredo, Carolina Aguayo, Claudia Ávila, Hugo Araya, Patricio Pérez, Felipe Berrios, Belén Agüero, Vanessa Mendieta, Edviges Maristela Pituco, Iassudara Garcia de Almeida, Rafael Medina, Barbara Brito, Magdalena Johow, Victor Neira Ramirez   +21 more
openaire   +4 more sources

Abstract LB039: Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV

Cancer Research, 2021
Abstract Seneca Valley Virus (SVV-001) is an oncolytic virus that has only been tested as a single dose intravenous monotherapy in early clinical trials of patients having cancers with neuroendocrine properties (e.g., NET, NEC). Recent data in the oncolytic and immunotherapy fields have demonstrated that oncolytic viruses can enhance ...
Paul L. Hallenbeck, Sunil Chada, Zachary S. Morris, Amber M. Bates, Amy K. Erbe   +4 more
openaire   +2 more sources

Abstract 6218: Oncolytic Seneca Valley virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model

Cancer Research, 2022
Abstract Here we evaluated the efficacy of Seneca Valley Virus (SVV), an oncolytic virus in the Picornaviridae family, in combination with checkpoint inhibitors (CPI) using the CPI-resistant murine syngeneic pancreatic tumor model Pan02.
Paul L. Hallenbeck, Sunil Chada
openaire   +2 more sources

Pathogenicity of two Chinese Seneca Valley virus (SVV) strains in pigs

Microbial Pathogenesis, 2019
Seneca Valley virus (SVV) has been identified as the causative agent of SVV-associated vesicular disease (SAVD). To investigate the pathogenicity of two newly isolated SVV strains (GD-S5/2018 and GD04/2017) in China, experimental infections of pigs were performed.
Lulu, Chen, Jialong, Zhang, Minmin, Wang, Shuonan, Pan, Chunxiao, Mou, Zhenhai, Chen   +5 more
openaire   +3 more sources

Abstract 5675: Optimization of a Seneca Valley Virus (SVV) 3C protease substrate for virus-directed enzyme prodrug therapy.

Cancer Research, 2013
Abstract Lung cancer is the leading cause of death among cancer patients, killing more than prostate, breast, and colon cancers combined. Extensive stage small cell lung cancer (ES-SCLC) has a median survival time of less than 12 months with current cytotoxic therapies.
Linde A. Miles, John T. Poirier, Charles M. Rudin   +2 more
openaire   +2 more sources

Abstract 4356: Identification of the anthrax toxin receptor (ANTXR1) as the high affinity cellular receptor for Seneca Valley Virus (SVV)

Cancer Research, 2016
Abstract Small cell lung cancer (SCLC) is an extremely aggressive and almost universally lethal form of lung cancer, which accounts for approximately 15% of all lung cancer diagnoses annually. Novel and more effective therapies are desperately needed for SCLC, as the standard treatment has not improved in almost three decades.
Linde A. Miles, J.T. Poirier, Charles M. Rudin   +2 more
openaire   +2 more sources